KN 060
Alternative Names: KN-060Latest Information Update: 15 Jan 2024
At a glance
- Originator Alphamab Oncology
- Class Antithrombotics; Bispecific antibodies; Immunoglobulin Fc fragments; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Factor XI inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Venous thromboembolism
Most Recent Events
- 03 Jan 2024 KN 060 is available for licensing as of 03 Jan 2024. http://www.alphamab.com/en/cooperation/index.html
- 20 Dec 2023 Phase-II clinical trials in Venous thromboembolism (Prevention) in China (IV) (NCT06180889)
- 20 Dec 2023 Phase-II clinical trials in Venous thromboembolism (Prevention) in China (IV) (NCT06180889)